Histidine-rich glycoprotein, a plasma component the concentration of which changes in various physiological and clinical conditions (Morgan et al., 1978; Lijnen et al., 1981a,b; Saitoetal., 1981 Saitoetal., ,1982 Jespersen&Kluft, 1982), is of uncertain function (Haupt & Heimburger, 1972; Heimburger et al., 1972) but exhibits a range of properties in vitro.
gation of platelets.
Sources of bovine thrombin (Kindness et al., 1979a) and of sulphated polysaccharides (Kindness et al., 1979a,b,c) were as previously described. Human platelet-rich plasma (Kindness et al., 19790) and purified rabbit histidine-rich glycoprotein (Morgan & Smith, 1983 ) were prepared as previously described. Thrombin, polysaccharides and histidine-rich glycoprotein were dissolved and diluted in 0.1 1 MNaCI/O.OSM-Tris/HCl, pH7.4. Polysaccharides and histidine-rich glycoprotein (59pg/ml) were incubated at 37°C for 120s; lop1 of the mixture were then added to 140p1 of platelet-rich plasma at 37°C. After 60s, lop1 of thrombin (0.3 units/ml) were added, and aggregation of platelets monitored in an aggregometer and microscopically as previously described (Kindness et al., 1979~) . Quoted concentrations of thrombin, polysaccharides and histidine-rich glycoprotein are final concentrations in the plasmacontaining reaction mix. Recorded outputs from the aggregometer were traced and superimposed graphically for convenient presentation. Fig. 1 shows that preincubation of heparin (0.03-0.06pg/ml) with histidine-rich glycoprotein alleviated the inhibitory effect of the polysaccharide on thrombin-induced aggregation. In the absence of heparin, histidine-rich glycoprotein itself did not affect thrombin-induced aggregation. Similarly, preincubation of histidine-rich glycoprotein with I-carrageenan (3.0-4.5 pg/ml), K-carrageenan (30pl/ml), icarrageenan (45pg/ml), dextran sulphate (0.3pg/ml); cellulose sulphate (0.6pg/ml) or xylan sulphate (0.6-3.0pg/ml) alleviated inhibition of thrombin-induced aggregation caused by these sulphated polysaccharides at the stated concentrations. Microscopic observations were in accord with results seen in the aggregometer. Under the conditions used, in the absence of thrombin, neither polysaccharides nor histidine-rich glycoprotein, together or separately, The mechanism by which heparins (and structurallyrelated polysaccharides) inhibit thrombin-induced platelet aggregation is not clear. It may involve potentiation of antithrombin 111 action, and presumably does involve interaction of thrombin with heparin, to which this proteinase is known to bind avidly (Jordan et al., 1980) . The neutralization of heparin anti-thrombin activity reported here accords with its neutralization of heparin anti-thrombin anti-factor Xa (EC 3.4.21.6) and anticoagulant activity in other assay systems reported elsewhere (Lijnen et a/., 1983a,b) . Histidine-rich glycoprotein is released from thrombin-treated platelets (Leung et al., 1982) ; functional counterparts of its in vitro heparin-neutralizing activities may include its modulation of the properties of platelet and endothelial cell heparans. In an attempt to define virulence factors in Salmonellosis a series of transposon-insertion mutants was prepared from a virulent wild-type Salmonella dublin isolate. Any mutants which showed reduced ability to kill mice were further characterized. Results suggest that there is plasmid involvement in the virulence of s. dublin.
Transposon-insertion mutagenesis of S. dublin 2229 was performed as described by Baird & Manning (1984) . The virulence of each mutant was assayed in mice (Table I) . Plasmid DNA was prepared either by the rapid method of Birnboim & Doly (1979) or, for cleaner preparations, by a similar scaled-up method (Baird & Manning, 1984) . Plasmid DNA samples were run on 0.6% agarose gels in a horizontal system using a Tris/acetate buffer (40mM-Tris, 5mM-sodium acetate, ~~M -E D T A , pH7.8) at IOOV for 5h, or 30V for 16h.
To date some 250 Tnl mutants of S. dublin 2229 have been assayed for virulence in mice. Only two mutants have shown diminished virulence (M51 and M173) and in both cases infectivity is reduced by 4-5 logs (Table I) . Virulence is also reduced in rats (results not shown). There is some indication that the mutant strains protect mice and rats against a subsequent challenge with the parent 2229 strain, but protection is limited (results not shown). We have shown in pathogenesis studies that M5 1 and M 173 are still able to invade the gut in mice, but accumulation in tissues such as blood and spleen is, at a given dose, less than that of the parent 2229 strain (Baird & Manning, 1984) .
Plasmid analyses have shown that S. dublin 2229 carries a single plasmid species, approximately 50 Md in size. Restriction-digest patterns have shown that, in both mutants, Tnl is inserted into the plasmid DNA. In each mutant the transposon has been shown to be inserted into the same SulI fragment, but into different EcoRI and Hind111 fragments. This information has enabled us to construct a tentative map (Baird & Manning, 1983) and to suggest that the insertion (and therefore mutation) in M51 is 10-15 kb from the insertion/mutation site in M173. To date we have not identified the gene products in 2229 which have been affected in M51 and M173, but we have cloned the appropriate fragments of the plasmid from 2229, M51 and MI73 into pACYC184 and are at present attempting to identify the protein products of these clones.
Abbreviations used: kb, kilobases; Md, megadaltons. 014 We have shown that the mutants are identical to the parent strain with respect to the presence of 0 and H antigens, serum resistance, sugar fermentations, motility, antibiotic resistances, nutritional requirements, haemagglutins, and, from preliminary experiments, the absence of enterotoxin.
There are many reports of plasmid involvement in bacterial virulence. In the salmonellosis field, Jones el al. (1982) here shown that loss of a 60Md plasmid from Salmonella typhimurium reduces infectivity in mice, which they attributed to the loss of plasmid-encoded adhesion/in vasion properties. Recently Terakado et al. (1983) have cured a 50Md plasmid from a S. dublin isolate and shown loss of virulence. However, these workers used ethidium bromide and they were unable to prove that they had not introduced other mutations during the curing process. Also they seem not to have a marker with which to select for plasmid-free variants.
Thus our work so far shows that a 50 Md plasmid plays an unidentified role in S. dublin virulence. However, avirulent isolates of S. dublin also contain a plasmid of apparently 50Md in size (E. J. Manning, unpublished work; Jones et al., 1984), but the functional integrity of the plasmid in each isolate is unknown. These sorts of problems will be solved when we are able to identify plasmid gene products.
